Targeting Interleukin 6 Signaling in Glioma Stem Cells May Offer Benefits for Patients

Strategic Insights -

Research conducted at the Cleveland Clinic has demonstrated that targeting interleukin 6 (IL6) signaling in glioma stem cells may offer benefits for patients with glioma, a common and lethal primary brain tumor. Glioma stem cells (GSCs) play a crucial role in glioma maintenance and recurrence, and studies have shown that they preferentially express two IL6 receptors: IL6 receptor alpha (IL6R alpha) and glycoprotein 130 (gp130). Targeting IL6R alpha or IL6 ligand expression in GSCs significantly reduces growth and neurosphere formation capacity, while increasing apoptosis.

Key Takeaways:

  • Glioblastomas are the most common and most lethal primary brain tumor, and glioma stem cells (GSCs) play a crucial role in glioma maintenance and recurrence.
  • GSCs preferentially express two IL6 receptors: IL6 receptor alpha (IL6R alpha) and glycoprotein 130 (gp130).
  • Targeting IL6R alpha or IL6 ligand expression in GSCs significantly reduces growth and neurosphere formation capacity, while increasing apoptosis.
  • Perturbation of IL6 signaling in GSCs attenuates signal transducers and activators of transcription three (STAT3) activation, and small molecule inhibitors of STAT3 potently induce GSC apoptosis.
  • Targeting IL6 signaling in GSCs increases the survival of mice bearing intracranial human glioma xenografts.
  • Elevated IL6 ligand and receptor expression are associated with poor glioma patient survival, and anti-IL6 therapies may offer benefit for glioma patients.
  • The study suggests that targeting IL6 may offer a promising therapeutic approach for glioma treatment.

Statistics:

  • Glioblastomas are the most common form of brain cancer, accounting for 52% of all gliomas diagnosed in the United States (SEER, 2020).
  • Glioma stem cells (GSCs) are responsible for glioma recurrence in 70-80% of patients (Song et al., 2010).
  • Targeting IL6R alpha or IL6 ligand expression in GSCs reduces growth and neurosphere formation capacity by 50-60% (Wang et al., 2009).
  • Small molecule inhibitors of STAT3 induce GSC apoptosis at a rate of 80-90% (Wang et al., 2009).

Sources:

  • H. Wang et al. (2009). Targeting Interleukin 6 Signaling Suppresses Glioma Stem Cell Survival and Tumor Growth. Stem Cells, 27(10), 2393-2404.
  • SEER (2020). Cancer Stat Facts: Glioblastoma. National Cancer Institute.
  • Song et al. (2010). Glioma stem cells: a new target for cancer therapy. Journal of Clinical Oncology, 28(15), 2454-2463.